Hubungan Kepatuhan Terapi Kelasi Dengan Kadar Feritin Serum Pada Pasien Thalasemia B Mayorpada Anak Di Rsam Provinsi Lampung

Zulhafis Mandala -  Universitas Malahayati, Indonesia
Festy Lady -  Universitas Malahayati, Indonesia
Muhammad Fahrin Ramadhan* -  Universitas Malahayati, Indonesia

ABSTRACT: RELATIONSHIP OF COMPLIANCE WITH KELSI THERAPY WITH SERUM FERITIN LEVELS IN THALASSEMIA β MAYOR PATIENTS IN CHILDREN AT BANDAR LAMPUNG HOSPITAL

 

Background: Thalassemia is a heterogeneous group of hereditary anemia caused by mutations in hemoglobin synthesis (Cunningham et al., 2009). In the world, thalassemia annually reaches 1 in 100,000 people. The incidence of thalassemia in the world is based on data from the World Health Organization or the World Health Organization

Purpose To determine the relationship between chelation therapy provision and serum ferritin levels in Thalassemia B Mayor patients in Dr. Hi Abdul Moeloek, Lampung Province in 2019.

Aim: To find out the relationship between the adherence to iron therapy with serum ferritin levels at RSAM in 2019.

Methods: This research is quantitative with the observational analytic method with a cross-sectional approach. The total population was 115 patients. A sample of 60 patients thalassemia β mayor. This research was conducted from Feb 2020 to completion. Analysis through univariate analysis.

Results: the relationship of compliance with kelasi therapy with serum feritin levels in thalasemia β mayor patients at rsam hospital 2019, 34 respondents who obeyed chelation therapy, as many as 21 respondents (61.8%) had no risk ferritin levels (≤1000), of the 36 respondents who did not comply with chelation therapy, as many as 6 respondents (23.1%) had levels ferritin No Risk (≤1000) The results of the analysis also obtained an OR value of 5.38 (95% CI 1.7-16.9), which means that respondents who are adherent to iron therapy are at risk of having ferritin levels at risk (≥ = 1000) 5.38 times greater than who do not adhere to iron therapy.

Conclusion: It is known that there is a relationship between adherence to iron therapy and serum ferritin levels at rsam hospital in 2019.

 

Keywords: Thalassemia, Iron Therapy, Ferritin Levels


INTISARI: HUBUNGAN KEPATUHAN TERAPI KELASI DENGAN KADAR FERITIN SERUM PADA PASIEN THALASEMIA β MAYOR PADA ANAK DI RSAM BANDAR LAMPUNG

 

Latar Belakang : Thalasemia merupakan salah satu kelompok heterogen anemia herediter yang disebabkan oleh mutasi pada sintesis hemoglobin (Cunningham et al., 2009). Di dunia, insiden thalasemia setiap tahunnya diperkirakan mencapai 1 dari 100.000 orang. Angka kejadian penyakit thalasemia di dunia berdasarkan data  dari Badan Organisasi Kesehatan Dunia atau World Health Organization

Tujuan Mengetahui hubungan kepatuhan terapi kelasi dengan kadar feritin serum pada pasien Thalasemia B Mayor Di RSUD Dr. Hi Abdul Moeloek Provinsi Lampung Tahun 2019

Metode Penelitian : Penelitian ini adalah kuantitatif dengan metode analitik observasional dengan pendekatan cross sectional. Jumlah populasi 115 pasien. Sampel 60 pasien dengan diagnosis thalassemia β mayor. Peneltian ini dilakukan pada bulan februari 2020 sampai dengan selesai. Analisa melalui analisa bivariat.    

Hasil : hubungan kepatuhan terapi kelasi dengan kadar ferritin serum pada pasien thalsemia β mayor di RSAM bandar lampung tahun 2019 34 responden yang patuh dalam terhadap terapi kelasi, sebanyak 21 responden (61,8%) memiliki kadar ferritin Tidak Beresiko (≤1000), dari 36 responden yang tidak patuh dalam terhadap terapi kelasi, sebanyak 6 responden (23,1%) memiliki kadar ferritin Tidak Beresiko (≤1000. Hasil analisis diperoleh pula nilai OR 5,38 (95% CI 1,7-16,9) yang berarti bahwa responden yang patuh dalam terhadap terapi kelasi, berisiko memiliki kadar feritin beresiko (≥=1000) 5,38 kali lebih besar dibandingkan dengan yang tidak patuh dalam terhadap terapi kelasi.

Kesimpulan : Diketahui terdapat hubungan kepatuhan terapi kelasi dengan kadar ferritin serum di RSAM Bandar Lampung tahun 2020

 

Kata kunci     :  Thalasemia, Terapi Kelasi, Feritin Serum
  1. Alymara, V., Bourantas, D., Chaidos, A., Bouranta, P., Gouva, M., Vassou, A. et al. (2004). Effectiveness and Safety of Combined Iron-Chelation Therapy with Deferoxamine and Deferiprone. The Hematology Journal. 5:475–479.
  2. Atmakusuma, D. (2009). Thalassemia:Manifestasi Klinis, Pendekatan Diagnosis, dan Thalassemia Intermedia. Dalam Sudoyo, A.W., Setiyohadi, B., Alwi, I., Simadibra, M., Setiati, S. Buku Ajar Ilmu Penyakit Dalam edisis V. Jakarta: Pusat Penerbitan Ilmu Penyakit Dalam, hal 1387-1393.
  3. Bakr, A.,Al-Tonbary, Y., Osman, G., El-Ashry, R. (2014). Renal Complications of Beta-Thalassemia Major in Children.Am J Blood Res. 4(1):1-6.
  4. Cappellini, M. D. (2012). Goldman Cecil Medicine. Elsavier, 1060-1066.
  5. Celc, A., Laura, M., Mariagrazia, F., Franco, B., Angela, C., Marcello, C. et al., (2011). TheManagement of Iron Chelation Therapy: Preliminary Data from a National Registry of Thalassaemic Patients.Hindawi Publishing Corporation Anemia vol 2011:1-7.
  6. Chaudhary, P., Pullarkat, V. (2013). Deferasirox: appraisal of safety and efficacy in long-term therapy. J Blood Med. 5(4):101-10.
  7. Cianciulli, P. (2009). Iron Chelation Therapy in Thalassemia Syndromes. Medit J Hemat Infect Dis. 1 (1).
  8. Cunningham, M.J., Sankaran, V.G., Nathan, D.G,, Orkin, S.H. Dalam Orkin SH, Nathan DG, Ginsburg D, Look AT, Fisher DE, Lux SE. Hematology of Infancy and Childhood.7th Edition. Canada. Page 1015-1059.
  9. Ferri, F. F. (2015). Ferri's Clinical Advisor . Elsevier, hal 1156-1157.
  10. Galanello, R., Origa, R. (2010). Beta-thalassemia.Galanello and Origa Orphanet Journal of Rare Diseases. 5(11):1-15.
  11. Grosso, M., Sessa, R., Puzone, S., Storino, M.R., Izzo, P. (2012). Molecular Basis of Thalassemia. www.intechopen.com/ download /pdf /30556.
  12. Guidelines for the Clinical Care Of Patient with Thalassemia in Canada. (2009). Anemia Institute for Research & Education. Canada: Thalassemia Foundation of Canada.
  13. Health Technology Assessment Indonesia. (2009). Pencegahan Thalasemia. Dirjen Bina Pelayanan Medik Kementrian Kesehatan Republik Indonesia.
  14. Ibrahiem, O.A., Thabet, A.F. (2013). Deferasirox Versus Deferoxiamine for the Treatment of Transfusional Iron Overload in Patients with β-Thalassemia Major. Ibnosina J Med BS. 6(1):14-18.
  15. Jamuar, S.S., Lai, A.H. M. (2012). Safety and Efficacy of Iron Chelation Therapy with Deferiprone in Patients with Transfusion-Dependent Thalassemia. Ther Adv Hematol. 3(5):299–307.
  16. Jimmy, B., Jose, J. (2011). Patient Medication Adherence: Measures in Daily Practice. Oman Medical Journal. 26 (3):155-159.
  17. Kidson-Gerber, G., Francis, S., Linderman, R. (2008). Management and Clinical Outcomes of Transfusion-dependent Thalassaemia Major in an Australian Tertiary Referral Clinic. MJA. 188;2.
  18. Kremastinos, DT., Farmakis, D., Aessopos, A., Hahalis, G., Hamodraka, E., Tsiapras, D. et al. (2010). β-thalassemia Cardiomyopathy History, Present Considerations, and Future Perspectives.Circ Heart Fail. 3:451-458.
  19. Kwiatkowski, J.L. (2008). Oral Iron Chelators. Elsavier; Pediatr Clin N Am. 55 (2008):461–482.
  20. Lal, A., Poter, J., Sweeters, N., Nq, V., Evans, P., Neumayr, L.et al. (2013). Combined Chelation Therapy with Deferasirox and Deferoxamine in Thalassemia. Elsavier; Blood Cells Mol Dis.50(2): 99–104.
  21. Makis, A., Chaliasos, N., Alfantaki, S., Karagouni, P., Siamopoulou, A. (2013). Chelation Therapy with Oral Solution of Deferiprone in Transfusional Iron-Overloaded Children with Hemoglobinopathies.Hindawi Publishing Corporation.
  22. Martin, A., Thompson, A. A. (2013). Thalassemias. Elsevier; Pediatr Clin N Am. 60: 1383–1391.
  23. Mashhadi, M.A., Rezvani, A.R., Naderi, M., Moghaddam, E. M. (2011). The Best Iron Therapy in Mayor Thalassemia Patients is Combination of Desferrioxamine and Deferiprone. International Journal of Hrmatology Oncology and Stem Cell Research. 5(2):19-22.
  24. Mishra, A.K., Tiwari, A. (2013). Iron Overload in Beta Thalassaemia Major and Intermedia Patients. MAEDICA –A Journal of Clinical Medicine. 8 (4):328-332.
  25. Orkin, S., Nathan, D.G., Ginsburg, D., Look, A.T., Fisher, D.E.,Lux, S.E. (2009). Hematology of Infancy and Childhood ed 7. Canada: Elsavier.
  26. Palit, S., Bhuiyan, R.H., Aklima, J., Emran, T.B., Dash, R. (2012). A Study of The Prevalence of Thalassemia and its Correlation With Liver Function Test in Different Age and Sex Group in the Chittagong District of Bangladesh. Journal of basic and clinical pharmacy. 3 (4): 352-357.
  27. Pedersini, R., Vietri, J. (2014). Comparison Of the 4-item and 8-item Morisky Medication Adherence Scale In Patient with Type 2 Diabete. Kantar Helath.
  28. Pedram, M., Khodamorad, Z., Bijan, Z., Reza, A., Akram, H., Fatemeh, K. et al. (2010). A Report on Chelating Therapy and Patient Compliance by Determination of Serum Ferritin Levels in 243 Thalassemia Major Patients.Iranian Journal of Pediatric Society. 2(2): 65-69.
  29. Pignatti, C.B., Cappellini, C.B., Stefano, P.D., Vecchio, G.C., Fomi, G.L., Gamberini, M.R.et al., (2006). Cardiac Morbidity and Mortality in Deferoxamine- or Deferiprone-Treated Patients with Thalassemia Major. The American Society of Hematology.107 (9):3733-3737
  30. Poggiali, E., Cassinerio, E., Zanaboni, L., Cappellini, M. D. (2012). An update on iron chelation therapy. Blood Transfus 2012. 10: 411-422.
  31. Porter, B., Evangeli, M. (2011). The Challenges of Adherence and Persistence With Iron Chelation Therapy. Int J Hematol. 94:453-460.
  32. Riaz, H., Riaz, T., Ubaid Khan, M., Aziz, S., Ullah, F., Rehaman, A, et al., (2011). Serum Ferritin Levels, Socio-demographic Factors and Desferrioxamine Therapy in Multi-transfused Thalassemia Major Patients at a Government Tertiary Care Hospital of Karachi, Pakistan. BMC Research Notes. 2011 (4):287.
  33. Rofail, D., Abetz, L., Viala, M., Gait, C., Baladi, J., Payne, K. (2009). Satisfaction and Adherence in Patients with Iron Overload Receiving Iron Chelation Therapy as Assessed by a Newly Developed Patient Instrument. International Society for Pharmacoeconomics and Outcomes Research (ISPOR). 12 (1).
  34. Rund, D., Rachmilewitz, E. (2006). β-thalassemia. N Eng J Med 2005. 3 (53):1135-1146.
  35. Sadiq Khan, M., Ahmed, M., Ali Khan, f., Mushtaq, N., Wasim, M. (2015). Consanguinity Ratio in β-thalassemia Major Patients in District Bannu. Department of Biotechnology, University of Science and Technology, KPK, Pakistan. 65:11.
  36. Sirachainan, N. (2013). Thalassemia and the hypercoagulable state. Elsevier. 132: 637-641.
  37. Tahir, H., Shahid, A., Mahmood, K.T. (2011). Complications in Thalassaemia Patients Receiving Blood Tranfusion. J Biomed Sci and Res. 3 (1):339-346.
  38. Tanner, M.A., Galanello, R., Dessi, C., Smith, G.C., Westwood, M.A., Agus, A.et al. (2008). Combined Chelation Therapy in Thalassemia Major for the Treatment of Severe Myocardial Siderosis with Left Ventricular Dysfunction. Journal of Cardiovascular Magnetic Resonance.10:12.
  39. Timan, I.S., Aulia, D.,Atmakusuma, D., Sudoyo, A., Windiastuti, E., Koasasih, A. (2002). Some Hematologi Problem in Indonesia. US National Library of Medicine National Institutes of Health.
  40. Trachtenberg, F., Mednick, L., Kwiatkowski, J., Neufeld, E., Haines, D., Pakbaz, Z, et al. (2012). Beliefs About Chelation Among Thalassemia Patients. Health and Quality of Life Outcomes 2012, 10:148.
  41. Zainaro, M. A. (2021). The Leadership and Motivation on Inpatient Compliance in Preventing the Risk of Patients Falling. Psychology and Education Journal, 58(2), 241-253.